Pharmac Proposes Expanded Access to Cystic Fibrosis Treatments for All Ages
核心洞察
Pharmac (搜索) has announced a provisional deal to fund Trikafta and new treatment Alyftrek for all ages from April 1, 2026, removing the current age restriction of six years and older.
The proposal would benefit approximately 35 people in the first year, expanding to 47 people after five years, with early intervention potentially preventing structural lung damage that occurs in 50-70% of children under six.
Public consultation is open until February 11, 2026, with the funding change representing a shift in Pharmac (搜索)'s approach to allow off-label prescribing and faster access to treatments.
New Zealand's pharmaceutical funding agency Pharmac (搜索) has announced a provisional agreement to expand access to life-changing cystic fibrosis (搜索) treatments, removing age restrictions that have forced families to consider relocating overseas for their children's care.
Associate Health Minister David Seymour confirmed the proposal would make Trikafta (elexacaftor/tezacaftor/ivacaftor) and new treatment Alyftrek (vanzacaftor/tezacaftor/deutivacaftor) available to all eligible patients from April 1, 2026, regardless of age. The announcement brings hope to families like the Rooneys, whose two-year-old son Luca was diagnosed with cystic fibrosis (搜索) just weeks after birth.
Addressing Critical Treatment Gaps
Currently, New Zealand's public funding for Trikafta is restricted to children aged six and older, leaving younger patients without access to treatment that can cost hundreds of thousands of dollars annually through private channels. This limitation has prompted at least five families known to Cystic Fibrosis NZ (搜索) to relocate to Australia or other countries to access treatment for their young children.
"That was probably the top of the list in terms of the option," said Liam Rooney when asked whether his family had considered moving overseas for Luca's treatment.
The proposal addresses a critical medical need, as research shows significant lung damage occurs very early in cystic fibrosis (搜索) patients. According to Cystic Fibrosis NZ (搜索)'s Simone Brown, "50% to 70% in studies show that children under the age of six will have on their first CT scans structural and bodily damage, and that's significant at age of one."
Expected Impact and Benefits
Pharmac (搜索)'s Director Pharmaceuticals Adrienne Martin noted that since Trikafta was funded in 2023 for people aged six years and above, over 400 people have benefited from the treatment. The expanded access proposal is expected to help approximately 35 people in the first year, increasing to 47 people after five years.
"Cystic fibrosis (搜索) starts causing harm very early in life. Funding these medicines for all age groups would help more young children with cystic fibrosis live longer, healthier lives," Martin explained. "It would also mean children could begin treatment as soon as clinically appropriate, giving families greater peace of mind."
The funding expansion would also benefit the healthcare system, as Martin indicated that "people wouldn't need to visit the hospital as often and they'd need less treatment."
Regulatory and Process Changes
The proposal represents a significant shift in Pharmac (搜索)'s approach to treatment access. Seymour outlined changes designed to avoid delays that previously affected younger children, explaining that decisions around eligibility were previously linked to medicine approval timing.
"The change that we've made this time is we've said, we're signing a contract with the provider to fund this, whether or not it is consented by MedSafe (搜索)," Seymour said. This approach would allow doctors to prescribe the medicines off-label, "put the trust in the physicians" and "get the medicine to the children faster."
Currently, Trikafta has Medsafe (搜索) regulatory approval for use in people aged two years and older, while Alyftrek is approved for children aged six and older.
Public Consultation Process
The proposal is not yet confirmed and requires public consultation before implementation. Pharmac (搜索) is seeking feedback from people with cystic fibrosis (搜索), their families, healthcare professionals, advocacy groups, and other interested parties. Consultation submissions close at 5pm on Wednesday, February 11, 2026, with funding set to begin from April 1, 2026, if the proposal is approved.
Seymour framed the announcement as evidence of a cultural shift within Pharmac (搜索), stating, "Pharmac used to be banging heads with everyone all the time. Now it is collaborating and looking for solutions."
For families affected by cystic fibrosis (搜索), the proposal offers hope for earlier intervention and improved outcomes. As Liam Rooney noted, "Knowing [Luca] can get Trikafta means we hopefully don't have to see the worst of what can happen. We've been told it's the most transformative drug there's ever been for this condition."